PD‐1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication
Authors:
- 4 March 2013
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 20 (s1) , 27-39
Abstract
Summary: α‐Galactosylceramide (α‐GalCer)‐activated natural killer T (NKT) cells have antiviral properties against hepatitis B virus (HBV). However, α‐GalCer activation of NKT cells can induce anergy. We hypothesized that this effect may be overcome by a treatment strategy that includes manipulation of CD28/CD80 costimulatory and PD‐1/PDL1 coinhibitory signals of NKT cells, thereby enhancing the anti‐HBV effect of α‐GalCer. We established a transgenic mouse model of chronic HBV infection and investigated hepatic NKT cell frequencies, functions and expression of immunomodulatory factors. Our results showed that compared with uninfected control mice, hepatic NKT cells from HBV transgenic mice displayed lower frequencies (7.91% vs 16.74%, P < 0.05), impaired capabilities to produce interferon (IFN)‐γ (5.6% vs 1.4%, P < 0.05) and interleukin (IL)‐4 (6.8% vs 0.3%, P < 0.05), higher expression of PD‐1 (9.64% vs 6.36%, P < 0.05) and lower expression of CD28 (5.05% vs 28.88%, P < 0.05). However, when hepatic mononuclear cells (MNCs) were isolated from HBV transgenic mice, α‐GalCer exposure in culture remarkably upregulated both PD‐1+ NKT cells (P < 0.05) and CD28+ NKT cells (P < 0.05). Furthermore, when HBV transgenic mice were treated with combination therapies consisting of α‐GalCer and anti‐PDL1 monoclonal antibody (mAb) and/or anti‐CD80/anti‐CD28 mAbs, IFN‐γ+ NKT cell frequency was selectively increased (P < 0.05) and HBV replication was suppressed; these effects were accompanied by varying degrees and types of liver damage. Surprisingly, activating CD28/CD80 signal in HBV transgenic mice was more effective but caused less liver injury than blocking PD‐1/PDL1 signal in modulating αGalCer‐activated NKT cell function to inhibit HBV infection. Our findings also show that combined therapy with blocking PD‐1/PDL1 and activating CD28/CD80 signal in the presence of aGalCer cannot superimpose the effect of antivirus. α‐GalCer combination therapy that modulates the CD28/CD80 pathways of NKT cells may represent a promising approach to inhibit HBV replication in chronically infected patients.Keywords
This publication has 33 references indexed in Scilit:
- Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma modelCancer Immunology, Immunotherapy, 2011
- Immune effectors required for hepatitis B virus clearanceProceedings of the National Academy of Sciences, 2009
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directionsMucosal Immunology, 2009
- CD28 Co-Stimulation Down Regulates Th17 DevelopmentPLOS ONE, 2009
- Severe functional impairment and elevated PD‐1 expression in CD1d‐restricted NKT cells retained during chronic HIV‐1 infectionEuropean Journal of Immunology, 2009
- PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT CellsThe Journal of Immunology, 2009
- T-Cell Costimulation and Coinhibition in AtherosclerosisCirculation Research, 2008
- α-Galactosylceramide in Chronic Hepatitis B Infection: Results from a Randomized Placebo-Controlled Phase I/ II TrialAntiviral Therapy, 2008
- Modulation of NKT Cell Development by B7-CD28 Interaction: An Expanding Horizon for CostimulationPLOS ONE, 2008
- ICOS costimulates invariant NKT cell activationBiochemical and Biophysical Research Communications, 2005